The reason, there's no talk of a ph3 for T2D - because, we're still conducting the ph2 program - you can't go to regulators with half a program to request ph3 approval - not even in Japan!
Part "a") of the T2D's programs was successful, it demonstrated a positive impact of the condition, in a safe, dose dependent manner! Part "b") is ongoing and is what everyone is REALLY waiting for, if they can deliver evidence of efficacy in Part "b" the likes of the USFDA will highly likely give them "fast-track" designation, MSB is already on the public record saying this is one area they most certainly would be of a mind to seek it - the Jap's will let them into the marketplace and MSB will be a game changer in the medical world!
MSB Price at posting:
$5.75 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)